Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Oct 9, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
11
Recruiting, any sponsor type, condition "hepatitis C"
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed1,331
11 trials
Showing 1 to 11, recently updated first.
- Simplifying Hepatitis C Pathways for People Who Inject Drugs in Armenia, Georgia, and TanzaniaRecruiting
Médecins du MondeAcademic, hospital or other
NCT06159504 · 3,040 participants (planned) · Start Oct 3, 2024 · Primary completion Dec 2026
Drug: sofosbuvir/velpatasvir (SOF/VEL) · For: Hepatitis C; RDT
Sites: Yerevan, Armenia
- Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United StatesPivotal-lookingRecruiting
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
NCT05832229 · 260 participants (planned) · Start Dec 7, 2023 · Primary completion Aug 31, 2029
Drug: Rosuvastatin · For: Cirrhosis; Cirrhosis, Liver; Cirrhosis Early and 5 more
Sites: La Jolla, California; Los Angeles, California; San Francisco, California · 13 sites in all
- Safety and Efficacy of Decentralized HCV Treatment vs Standard-of-Care in Rio de Janeiro (Brazil)Pivotal-lookingRecruiting
Oswaldo Cruz FoundationAcademic, hospital or other
NCT06306300 · 30,000 participants (planned) · Start Jul 4, 2022 · Primary completion Dec 31, 2026
Drug: Specialist - Epclusa 400Mg-100Mg Tablet; Non- specialist - Epclusa 400Mg-100Mg Tablet · For: Hepatitis C
Sites: Rio de Janeiro, Brazil · 2 sites in all
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT07040319 · 30 participants (planned) · Start Jun 25, 2026 · Primary completion Mar 3, 2028
Drug: Glecaprevir/pibrentasvir · For: Hepatitis C
Sites: Los Angeles, California; Aurora, Colorado; Jacksonville, Florida · 10 sites in all
Kirby InstituteGovernment (non-federal)
NCT03855917 · 30 participants (planned) · Start Feb 11, 2020 · Primary completion Jul 31, 2029
Drug: Sofosbuvir 400mg [Sovaldi]; Glecaprevir/pibrentasvir (300mg/120mg) · For: Hepatitis C
Sites: Darlinghurst, Australia; Sydney, Australia; Adelaide, Australia
Washington University School of MedicineAcademic, hospital or other
NCT06367465 · 50 participants (planned) · Start Feb 1, 2024 · Primary completion Dec 28, 2026
Drug: Glecaprevir-pibrentasvir · For: Hepatitis C; Pregnancy Complications
Sites: St Louis, Missouri · 2 sites in all
LifespanAcademic, hospital or other
NCT06953479 · 40 participants (planned) · Start Jun 11, 2025 · Primary completion Jan 2027
Drug: Sofosbuvir / Velpatasvir Oral Tablet [Epclusa] · For: HEPATITIS C (HCV); Incarceration; Injection Drug Use and 1 more
Sites: Cranston, Rhode Island
Baylor Research InstituteAcademic, hospital or other
NCT03383419 · 15 participants (planned) · Start Mar 20, 2018 · Primary completion Dec 30, 2026
Drug: Epclusa · For: Heart Failure
Sites: Los Angeles, California; Durham, North Carolina; Dallas, Texas
The Task Force for Global HealthAcademic, hospital or other
NCT05368974 · 100 participants (planned) · Start Feb 11, 2022 · Primary completion Jun 30, 2026
Drug: Direct Acting Antivirals · For: Hepatitis C
Sites: Atlanta, Georgia
The Third Affiliated Hospital of Guangzhou Medical UniversityAcademic, hospital or other
NCT06180590 · 200 participants (planned) · Start Feb 28, 2023 · Primary completion Feb 28, 2026
Drug: Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi] · For: Chronic Hepatitis C; Medication Reaction
Sites: Guangzhou, China
- Effect of Some Drugs on Liver FibrosisPivotal-lookingRecruiting
Sherief Abd-ElsalamAcademic, hospital or other
NCT03770936 · 45 participants (planned) · Start Oct 1, 2018 · Primary completion Oct 2026
Drug: Candesartan; Ramipril · For: Liver Fibroses
Sites: Tanta, Egypt
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.